Bailard’s Bio-Path Holdings Inc BPTH Stock Holding History

Bailard’s Portfolio BPTH Stock Details BPTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,676	Closed	-$126K	–	821
2021 Q4	$126K	Buy	+1,676	New	+$155K	﹤0.01%	706

Other funds holding BPTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Bailard's BPTH Position: Q1 2022 in Review

Bailard sold out of Bio-Path Holdings Inc (BPTH) in Q1 2022, closing a stake of 1,676 shares — an estimated $126K sold.

Bailard first reported a position in BPTH in Q4 2021 and held it in 1 quarter. The position peaked at $126K in Q4 2021. 17 funds tracked by Wall St. Rank hold BPTH as of Q1 2022.

Bailard reported no remaining Bio-Path Holdings Inc position as of Q1 2022 after selling out during the quarter.
Bailard sold 1,676 Bio-Path Holdings Inc shares in Q1 2022, an estimated $126K.
Bailard first reported a position in Bio-Path Holdings Inc in Q4 2021 and held it in 1 quarter.
Bailard's Bio-Path Holdings Inc position peaked at $126K in Q4 2021.
17 funds tracked by Wall St. Rank held Bio-Path Holdings Inc as of Q1 2022.

Based on Bailard's 13F filing for Q1 2022, filed 25 Apr 2022.